Affordable Access

deepdyve-link
Publisher Website

Development and validation of the Uniform Data Set (v3.0) executive function composite score (UDS3-EF).

Authors
  • Staffaroni, Adam M1
  • Asken, Breton M1
  • Casaletto, Kaitlin B1
  • Fonseca, Corrina1
  • You, Michelle1
  • Rosen, Howard J1
  • Boxer, Adam L1
  • Elahi, Fanny M1
  • Kornak, John2
  • Mungas, Dan3
  • Kramer, Joel H1
  • 1 Department of Neurology, Memory and Aging Center, Weill Institute for Neurosciences, University of California at San Francisco (UCSF), San Francisco, California, USA.
  • 2 Department of Epidemiology and Biostatistics, Memory and Aging Center, University of California at San Francisco (UCSF), San Francisco, California, USA.
  • 3 Department of Neurology, University of California, Davis, Davis, California, USA.
Type
Published Article
Journal
Alzheimer's & dementia : the journal of the Alzheimer's Association
Publication Date
Apr 01, 2021
Volume
17
Issue
4
Pages
574–583
Identifiers
DOI: 10.1002/alz.12214
PMID: 33215852
Source
Medline
Keywords
Language
English
License
Unknown

Abstract

Cognitive composite scores offer a means of precisely measuring executive functioning (EF). We developed the Uniform Data Set v3.0 EF composite score (UDS3-EF) in 3507 controls from the National Alzheimer's Coordinating Center dataset using item-response theory and applied nonlinear and linear demographic adjustments. The UDS3-EF was validated with other neuropsychological tests and brain magnetic resonance imaging from independent research cohorts using linear models. Final model fit was good-to-excellent: comparative fit index = 0.99; root mean squared error of approximation = 0.057. UDS3-EF scores differed across validation cohorts (controls > mild cognitive impairment > Alzheimer's disease-dementia ≈ behavioral variant frontotemporal dementia; P < 0.001). The UDS3-EF correlated most strongly with other EF tests (βs = 0.50 to 0.85, Ps < 0.001) and more with frontal, parietal, and temporal lobe gray matter volumes (βs = 0.18 to 0.33, Ps ≤ 0.004) than occipital gray matter (β = 0.12, P = 0.04). The total sample needed to detect a 40% reduction in UDS3-EF change (n = 286) was ≈40% of the next best measure (F-words; n = 714). The UDS3-EF is well suited to quantify EF in research and clinical trials and offers psychometric and practical advantages over its component tests. © 2020 The Authors. Alzheimer's & Dementia published by Wiley Periodicals LLC on behalf of Alzheimer's Association.

Report this publication

Statistics

Seen <100 times